Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 26-50 of 450 citing articles:

Documento de consenso. Manejo de la enfermedad hepática grasa no alcohólica (EHGNA). Guía de práctica clínica
R. Aller, Conrado Fernández-Rodrı́guez, Oreste Lo Iacono, et al.
Gastroenterología y Hepatología (2018) Vol. 41, Iss. 5, pp. 328-349
Open Access | Times Cited: 98
Combination of Probiotics and Salvia miltiorrhiza Polysaccharide Alleviates Hepatic Steatosis via Gut Microbiota Modulation and Insulin Resistance Improvement in High Fat-Induced NAFLD Mice
Wei Wang, A Xu, Zheng-Chao Li, et al.
Diabetes & Metabolism Journal (2019) Vol. 44, Iss. 2, pp. 336-336
Open Access | Times Cited: 97
Diagnosis of non-alcoholic fatty liver disease (NAFLD)
Hannele Yki‐Järvinen
Diabetologia (2016) Vol. 59, Iss. 6, pp. 1104-1111
Open Access | Times Cited: 92
The influence of dietary fatty acids on liver fat content and metabolism
Leanne Hodson, Fredrik Rosqvist, Siôn Parry
Proceedings of The Nutrition Society (2019) Vol. 79, Iss. 1, pp. 30-41
Open Access | Times Cited: 80
FIB-4, APRI, and AST/ALT ratio compared to FibroScan for the assessment of hepatic fibrosis in patients with non-alcoholic fatty liver disease in Bandar Abbas, Iran
Behnaz Amernia, Seyed Hamid Moosavy, Fatemeh Banookh, et al.
BMC Gastroenterology (2021) Vol. 21, Iss. 1
Open Access | Times Cited: 76
Incorporating fatty liver disease in multidisciplinary care and novel clinical trial designs for patients with metabolic diseases
Mohammed Eslam, Aijaz Ahmed, Jean‐Pierre Després, et al.
˜The œLancet. Gastroenterology & hepatology (2021) Vol. 6, Iss. 9, pp. 743-753
Open Access | Times Cited: 73
Dietary Interventions in Patients With Non-alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
Veera Houttu, Susanne Csader, Max Nieuwdorp, et al.
Frontiers in Nutrition (2021) Vol. 8
Open Access | Times Cited: 72
Non-Alcoholic Fatty Liver Disease in Lean and Non-Obese Individuals: Current and Future Challenges
Mohammad Shafi Kuchay, José Ignacio Martínez‐Montoro, Narendra S. Choudhary, et al.
Biomedicines (2021) Vol. 9, Iss. 10, pp. 1346-1346
Open Access | Times Cited: 72
Positive Effects of Exercise Intervention without Weight Loss and Dietary Changes in NAFLD-Related Clinical Parameters: A Systematic Review and Meta-Analysis
Ambrin Farizah Babu, Susanne Csader, Johnson Lok, et al.
Nutrients (2021) Vol. 13, Iss. 9, pp. 3135-3135
Open Access | Times Cited: 71
Management of NAFLD in primary care settings
Vincent Wai‐Sun Wong, Shira Zelber‐Sagi, Kenneth Cusi, et al.
Liver International (2022) Vol. 42, Iss. 11, pp. 2377-2389
Closed Access | Times Cited: 53
The establishment of public health policies and the burden of non-alcoholic fatty liver disease in the Americas
Luis Antonio Díaz, Eduardo Fuentes‐López, Gustavo Ayares, et al.
˜The œLancet. Gastroenterology & hepatology (2022) Vol. 7, Iss. 6, pp. 552-559
Open Access | Times Cited: 49
Does moderate alcohol consumption accelerate the progression of liver disease in NAFLD? A systematic review and narrative synthesis
Helen Jarvis, Hannah O’Keefe, Dawn Craig, et al.
BMJ Open (2022) Vol. 12, Iss. 1, pp. e049767-e049767
Open Access | Times Cited: 43
Natural Compounds for Counteracting Nonalcoholic Fatty Liver Disease (NAFLD): Advantages and Limitations of the Suggested Candidates
Noel Salvoza, Pablo J. Giraudi, Claudio Tiribelli, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 5, pp. 2764-2764
Open Access | Times Cited: 41
Impact of a Mediterranean diet on hepatic and metabolic outcomes in non‐alcoholic fatty liver disease: The MEDINA randomised controlled trial
Elena S. George, Anjana Reddy, Amanda Nicoll, et al.
Liver International (2022) Vol. 42, Iss. 6, pp. 1308-1322
Open Access | Times Cited: 40
Prognostic utility of Fibrosis-4 Index for risk of subsequent liver and cardiovascular events, and all-cause mortality in individuals with obesity and/or type 2 diabetes: a longitudinal cohort study
Quentin M. Anstee, Tina Landsvig Berentzen, Louise Maymann Nitze, et al.
The Lancet Regional Health - Europe (2023) Vol. 36, pp. 100780-100780
Open Access | Times Cited: 39
Efficacy of probiotics on nonalcoholic fatty liver disease: A meta-analysis
Xiangyu Zhou, Jincheng Wang, Sufang Zhou, et al.
Medicine (2023) Vol. 102, Iss. 4, pp. e32734-e32734
Open Access | Times Cited: 27
Glutathione: Pharmacological aspects and implications for clinical use in non-alcoholic fatty liver disease
Giovanni Santacroce, Antonella Gentile, Simone Soriano, et al.
Frontiers in Medicine (2023) Vol. 10
Open Access | Times Cited: 25
Effect of an Asian-adapted Mediterranean diet and pentadecanoic acid on fatty liver disease: the TANGO randomized controlled trial
Yu Chung Chooi, Qinze Arthur Zhang, Faidon Magkos, et al.
American Journal of Clinical Nutrition (2023) Vol. 119, Iss. 3, pp. 788-799
Open Access | Times Cited: 22
Non-alcoholic fatty liver disease: pathogenesis and models
Hanxiang Zhong
American Journal of Translational Research (2024) Vol. 16, Iss. 2, pp. 387-399
Open Access | Times Cited: 13
Diagnostic Performance of Noninvasive Tests in Patients with MetALD in a Health Check-up Cohort
Joo Hyun Oh, Sang Bong Ahn, Seon Cho, et al.
Journal of Hepatology (2024)
Closed Access | Times Cited: 8
A European Survey to Identify Challenges in the Management of Metabolic Dysfunction‐Associated Steatotic Liver Disease
Laurent Castéra, William Alazawi, Elisabetta Bugianesi, et al.
Liver International (2025) Vol. 45, Iss. 2
Open Access | Times Cited: 1
Metabolic Dysfunction Associated-Steatotic Liver Disease (MASLD) and Cardiovascular Risk: Embrace All Facets of the Disease
Niki Katsiki, Genovefa Kolovou, Michal Vráblík
Current Cardiology Reports (2025) Vol. 27, Iss. 1
Closed Access | Times Cited: 1
Prevalence and determinants of non-alcoholic fatty liver disease in lifelines: A large Dutch population cohort
Eline H. van den Berg, Marzyeh Amini, T.C.M.A. Schreuder, et al.
PLoS ONE (2017) Vol. 12, Iss. 2, pp. e0171502-e0171502
Open Access | Times Cited: 83
Non-alcoholic fatty liver disease: controlling an emerging epidemic, challenges, and future directions
Andrew Ofosu
Annals of Gastroenterology (2018)
Open Access | Times Cited: 80
Nutritional issues in patients with obesity and cirrhosis
Luigi Schiavo, Luca Busetto, Manuela Cesaretti, et al.
World Journal of Gastroenterology (2018) Vol. 24, Iss. 30, pp. 3330-3346
Open Access | Times Cited: 70

Scroll to top